Cyclodextrin-assisted drug delivery to Central Nervous System: Mavenclad™ for multiple sclerosis treatment
In a recent study, Professors Bodor and Buchwald review the use of cyclodextrin-enabled formulations to develop oral tablets of cladribine
A forum for researchers, students and applicants in the field of cyclodextrin technology
In a recent study, Professors Bodor and Buchwald review the use of cyclodextrin-enabled formulations to develop oral tablets of cladribine
The central nervous system ( CNS) is increasingly recognized as a cholesterol-rich organ. While the brain accounts for approximately 5%
JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”). Beren Therapeutics is developing
All these studies utilize the high solubilizing effect of 2,6-di-O-methyl beta-cyclodextrin studying various model drugs. The compatibility, inclusion stability, and
Pediatric drug development faces notable challenges due to age-related physiological differences, with limited approved formulations often leading to off-label or
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress
The little we have learned and the many unknowns still waiting to be discovered. Cyclodextrins are commonly used as excipients
Oxidative stress is one of the key elements in lung-related complications such as cystic fibrosis, acute lung injury, pulmonary hypertension,
This review outlines the structural features of native CDs and their chemically modified derivatives, emphasizing the influence of functionalization on